Founded in 2007, Quanterix has developed an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. The Single Molecule Array (Simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant commercial unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. Quanterix is a venture capital backed company.... Read more

Unleashing the power of next-generation Simoa ® Planar Array technology for rob...

Quanterix is re-engineering ultrasensitivity with the launch of the Simoa HD-X Analy...

The Quanterix SR-X Ultra-Sensitive Biomarker Detection System™ is powered by Simoa ®...

The Simoa HD-1 analyzer leverages a unique, low-cost “smart” disc developed by Sony ...

Founded in 2007, Quanterix has developed an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today.

The Single Molecule Array (Simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant commercial unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more.

Quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at Tufts University by Dr. David Walt, scientific founder of Quanterix and Illumina (NASDAQ: ILMN).

Contact Quanterix

113 Hartwell Avenue, Lexington, MA 02421 USA
USA
+1 (617) 301-9400
Company Website